Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alclometasone Dipropionate

FDA-approved product (ointment, topical), marketed as Aclovate, Alclometasone Dipropionate.

Registered studies
2
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alclometasone Dipropionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye inflammation
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, moderately potent (group ii); Corticosteroids, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alclometasone Dipropionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alclometasone Dipropionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

    NCT01465802 · start 2011-12-26

    Registered record
    Registry ID
    NCT01465802
    Conditions
    Non Small Cell Lung Cancer (NSCLC)
    Interventions
    Dacomitinib; Dacomitinib; Doxycycline; Probiotic; Alclometasone cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-12-26
    Completion
    2015-05-18
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer (NSCLC)
    InterventionDacomitinib; Dacomitinib; Doxycycline; Probiotic +1 more
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream

    NCT02075632 · start 2006-09

    Registered record
    Registry ID
    NCT02075632
    Conditions
    Eczema; Allergy Symptoms; Psoriasis; Itch
    Interventions
    Alclometasone dipropionate cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-09
    Completion
    2006-11
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema; Allergy Symptoms; Psoriasis; Itch
    InterventionAlclometasone dipropionate cream
    PhasePhase 2
    Registry statusCompleted